Compare · DXCM vs LNSR
DXCM vs LNSR
Side-by-side comparison of DexCom Inc. (DXCM) and LENSAR Inc. (LNSR): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DXCM and LNSR operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- DXCM is the larger of the two at $28.11B, about 414.8x LNSR ($67.8M).
- Over the past year, DXCM is down 9.5% and LNSR is down 57.5% - DXCM leads by 47.9 points.
- DXCM has been more active in the news (26 items in the past 4 weeks vs 13 for LNSR).
- DXCM has more recent analyst coverage (25 ratings vs 3 for LNSR).
- Company
- DexCom Inc.
- LENSAR Inc.
- Price
- $77.51+6.40%
- $5.55+0.18%
- Market cap
- $28.11B
- $67.8M
- 1M return
- +27.14%
- +5.41%
- 1Y return
- -9.55%
- -57.47%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2005
- News (4w)
- 26
- 13
- Recent ratings
- 25
- 3
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
LENSAR Inc.
LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing an advanced femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. The company was incorporated in 2004 and is headquartered in Orlando, Florida.
Latest DXCM
- Dexcom CONNECT Study: The Most Significant Clinical Study Demonstrating CGM Benefits for People with Type 2 Diabetes Not Using Insulin
- EVP, Chief Commercial Officer Coleman Jon sold $722,628 worth of shares (9,823 units at $73.56) as part of a pre-agreed trading plan, decreasing direct ownership by 9% to 95,450 units (SEC Form 4)
- Dexcom Reaffirms CGM Benefits for All People With Diabetes and Continues Momentum Toward Earlier Stage Intervention and Preventative Care at ADA 2026
- Dexcom Releases Customer Advisory Council Report, Outlining Ongoing Commitments to Enhancing Product Performance and User Experience
- Director Altman Steven R was granted 5,565 shares (SEC Form 4)
- Director Augustinos Nicholas was granted 5,575 shares (SEC Form 4)
- Director Malady Kyle was granted 5,575 shares, increasing direct ownership by 25% to 28,242 units (SEC Form 4)
- Director Heller Bridgette P was granted 5,575 shares, increasing direct ownership by 22% to 30,582 units (SEC Form 4)
- Director Osterloh Albert Frederick Iv was granted 1,630 shares, increasing direct ownership by 23% to 8,691 units (SEC Form 4)
- Director Foletta Mark G was granted 6,331 shares (SEC Form 4)
Latest LNSR
- Director Hammer Todd B was granted 17,421 shares, increasing direct ownership by 45% to 56,083 units (SEC Form 4)
- Director Ellis Thomas B was granted 17,421 shares, increasing direct ownership by 45% to 56,083 units (SEC Form 4)
- Principal Accounting Officer Wong Kendra was granted 13,066 shares, increasing direct ownership by 30% to 56,481 units (SEC Form 4)
- Chief Operating Officer Connaughton Alan B. was granted 34,843 shares, increasing direct ownership by 10% to 389,173 units (SEC Form 4)
- Chief Executive Officer Curtis Nicholas T was granted 130,662 shares, increasing direct ownership by 13% to 1,122,758 units (SEC Form 4)
- Director Weisner Aimee S was granted 17,421 shares, increasing direct ownership by 19% to 110,368 units (SEC Form 4)
- Director O'Farrell Elizabeth G. was granted 17,421 shares, increasing direct ownership by 35% to 67,368 units (SEC Form 4)
- Director Winer Gary M was granted 17,421 shares, increasing direct ownership by 20% to 105,635 units (SEC Form 4)
- Director Lindstrom Richard L Md was granted 17,421 shares, increasing direct ownership by 7% to 263,831 units (SEC Form 4)
- Director Link William J Phd was granted 17,421 shares, increasing direct ownership by 3% to 568,062 units (SEC Form 4)